What is biphenotypic sinonasal sarcoma?
Biphenotypic sinonasal sarcoma (BSNS) is an uncommon cancer of the nose and sinuses that grows slowly. It belongs to the group of soft-tissue sarcomas, which are cancers of connective tissue. “Biphenotypic” means its cells show two kinds of features at once: some resemble nerve-sheath cells and some resemble muscle cells. It was first described as a separate disease only in 2012 and was originally called low-grade sinonasal sarcoma with neural and myogenic features.
BSNS almost always starts high in the nasal cavity or in the ethmoid sinuses, the honeycomb of small air spaces between the eyes. It mainly affects adults in middle age, and women are affected about twice as often as men.
The tumour is caused by a change in a gene called PAX3, which becomes fused to another gene, most often MAML3 (Wang et al., 2014). This gene change is so typical that testing for it helps confirm the diagnosis.
BSNS is described as low grade. It can grow into nearby structures such as the eye socket and the base of the skull, and it often comes back after surgery if not fully removed. However, spread to distant organs is extremely rare and deaths from the disease are uncommon (Carter, East and McHugh, 2018). Surgery, often by endoscopic (keyhole) techniques through the nose, is the main treatment.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Low-grade spindle cell sarcoma of the nose and sinuses |
| Former name | Low-grade sinonasal sarcoma with neural and myogenic features |
| How common | Very rare; a few hundred cases reported since 2012 |
| Typical age | Adults, average around 50; wide range |
| Sex | About twice as common in women |
| Main sites | Upper nasal cavity and ethmoid sinuses |
| Key gene change | PAX3 fusion, most often PAX3::MAML3 |
| Main treatment | Surgical removal, sometimes followed by radiotherapy |
| Outlook | Good survival; local recurrence is common |
2. Types of biphenotypic sinonasal sarcoma
All BSNS tumours share the same basic appearance, but they differ in the partner gene fused to PAX3.
| Fusion | Notes |
|---|---|
| PAX3::MAML3 | The most frequent; found in the majority of cases |
| PAX3::FOXO1 | Less common; also seen in alveolar rhabdomyosarcoma, a different cancer |
| PAX3::NCOA1 or PAX3::NCOA2 | Rare; some show areas of muscle-type (rhabdomyoblastic) differentiation |
| Other partners | Occasional rare fusions, such as WWTR1 or FOXO6 |
A very small number of tumours have been reported to change into a high-grade sarcoma, but this is exceptional.
How it differs from other nose and sinus cancers
| Feature | BSNS | Common sinonasal carcinomas |
|---|---|---|
| Cell type | Spindle cells (sarcoma) | Lining cells (carcinoma) |
| Link with smoking or wood dust | None known | Often present |
| Spread to lymph nodes | Almost never | Possible |
| Growth | Slow | Often faster |
| Main risk | Local recurrence | Local and distant spread |
Understanding the nose and sinuses
| Structure | Role and relevance to BSNS |
|---|---|
| Nasal cavity | The air passage behind the nose; the upper part is the most frequent starting point |
| Ethmoid sinuses | Small air cells between the eyes; very often involved |
| Frontal sinus | Above the eyes; may be blocked by the tumour |
| Maxillary sinus | In the cheek; involved less often |
| Eye socket (orbit) | Separated from the ethmoid sinuses by a paper-thin bone |
| Skull base (cribriform plate) | The thin roof of the nose, below the front of the brain; carries the nerves of smell |
Because the bone between the sinuses, the eye socket and the brain is so thin, even a slow-growing tumour can reach these areas before it causes obvious symptoms.
3. Causes and risk factors
The cause of BSNS is not known. The PAX3 fusion arises in the tumour cells during life. PAX3 normally helps guide the development of nerve and muscle tissue in the embryo, which explains why the tumour cells show features of both (Wang et al., 2014).
| Factor | Notes |
|---|---|
| Female sex | Women are affected more often |
| Middle age | Most patients are in their 40s to 60s |
| Environmental exposures | No clear link with smoking, wood dust or chemicals |
| Inherited conditions | None known |
The gene change is not inherited and cannot be passed on.
4. How does it look
From the outside
Usually there is nothing visible. Large tumours may cause swelling around the eye or a bulging eye.
Inside the nose
| Feature | Description |
|---|---|
| Appearance | A pink, fleshy, polyp-like mass |
| Surface | Usually smooth, covered by normal nasal lining |
| Position | High in the nasal cavity or ethmoid sinuses |
| Bleeding | May bleed when touched |
| Mistaken for | An ordinary nasal polyp |
On scans
CT shows how the tumour has affected the thin bones of the sinuses, eye socket and skull base. Bone may be thinned, pushed or thickened rather than aggressively destroyed. MRI shows the tumour’s extent into the eye socket, brain coverings and skull base, and helps distinguish tumour from trapped mucus.
Under the microscope
| Feature | Description |
|---|---|
| Cells | Uniform, slender spindle cells arranged in long bundles |
| Pattern | Herringbone or interlacing fascicles |
| Blood vessels | Thin-walled, branching vessels |
| Surface lining | Often shows invaginations of the overlying epithelium |
| Stains | S100 and smooth muscle actin positive; PAX3 positive |
| Molecular test | Detects the PAX3 fusion |
PAX3 staining is highly sensitive and specific for BSNS, helping to separate it from similar-looking tumours (Jo et al., 2018).
5. Symptoms
Common symptoms
- A blocked nose, often on one side, that does not clear
- Nosebleeds
- Pressure or pain around the nose, forehead or eyes
- Reduced sense of smell
- Headache
Less common symptoms
| Symptom | What it may mean |
|---|---|
| Watery eye | Blockage of the tear duct |
| Double vision or bulging eye | Growth into the eye socket |
| Swelling between the eyes | Local growth |
| Clear fluid from the nose | Rarely, a leak of brain fluid through the skull base |
| Facial numbness | Nerve involvement |
When to seek medical advice
See a doctor if you have a blocked nose on one side that lasts for weeks, repeated nosebleeds, or changes in your vision or eye position. Most of these symptoms are caused by common conditions, but one-sided symptoms should be checked by an ear, nose and throat (ENT) specialist.
6. Diagnosis
| Test | Purpose |
|---|---|
| Nasal endoscopy | A thin camera examines the inside of the nose |
| Biopsy | Tissue sample, usually taken in clinic or under anaesthetic |
| Immunohistochemistry | S100, smooth muscle actin and PAX3 stains |
| Molecular testing | Confirms the PAX3 fusion |
| CT of the sinuses | Shows bony changes |
| MRI of the head | Shows spread to the eye socket and skull base |
| Eye examination | If the eye socket may be involved |
Conditions that can look similar
| Condition | Notes |
|---|---|
| Nasal polyp | Common and benign; may look identical on examination |
| Schwannoma | Benign nerve sheath tumour |
| Malignant peripheral nerve sheath tumour | A more aggressive sarcoma |
| Synovial sarcoma | Another spindle cell sarcoma |
| Solitary fibrous tumour or glomangiopericytoma | Other sinonasal soft-tissue tumours |
Staging
There is no specific staging system. Doctors describe the extent of local spread, especially into the eye socket, skull base or brain coverings, because this determines the surgical approach.
7. Treatment
Treatment is planned by a skull base or head and neck team, usually including ENT surgeons, neurosurgeons, ophthalmologists and clinical oncologists.
Surgery
| Approach | When it is used |
|---|---|
| Endoscopic endonasal surgery | Most tumours; removed through the nostrils with a camera |
| Endoscopic transnasal craniectomy | When the tumour reaches the skull base; the skull base is repaired afterwards |
| Combined cranio-endoscopic approach | When the tumour extends into the skull |
| Open approaches | Occasionally for very large tumours |
The goal is complete removal with clear margins. In a European series of 15 patients treated by endoscopic-assisted approaches, all were alive at 5 years, and about 80% were free of disease (Turri-Zanoni et al., 2022).
Radiotherapy
| Situation | Role |
|---|---|
| Positive or close margins | May lower the risk of recurrence |
| Tumours that cannot be fully removed | For local control |
| Recurrent disease | After further surgery, or instead of it |
Modern techniques such as intensity-modulated radiotherapy or proton therapy help protect the eyes, optic nerves and brain.
Drug treatment
Chemotherapy has no established role. Research into the PAX3 fusion may lead to targeted treatments in the future.
Side effects
| Treatment | Possible side effects |
|---|---|
| Endoscopic surgery | Crusting, nasal blockage, bleeding, reduced sense of smell |
| Skull base surgery | Small risk of brain fluid leak or infection |
| Radiotherapy | Dryness and crusting in the nose, tiredness, dry eye; rarely, vision problems |
What treatment involves day to day
| Stage | What to expect |
|---|---|
| Endoscopic surgery | Usually 1-3 nights in hospital |
| Recovery | Nasal rinses several times a day for weeks |
| Skull base repair | Avoid nose-blowing, straining and heavy lifting for several weeks |
| Radiotherapy, if needed | Weekday sessions for about 5-6 weeks |
Recovery after endoscopic surgery
| Time after surgery | What is typical |
|---|---|
| First week | Blocked nose, mild bleeding, tiredness; avoid blowing the nose |
| Weeks 2-4 | Crusting gradually eases with rinses; clinic visit to clean the nose |
| Weeks 4-8 | Most people return to normal activities and work |
| Months 3-6 | Healing usually complete; first follow-up scan |
Your sense of smell may improve, stay the same or worsen, depending on how close the tumour was to the smell nerves.
8. Outlook (prognosis)
| Measure | Usual result |
|---|---|
| Survival | Very high; deaths from BSNS are rare |
| Local recurrence | Common, sometimes many years after treatment |
| Distant spread | Exceptionally rare |
| Most important factor | Complete removal with clear margins |
Recurrences can usually be treated with further surgery or radiotherapy. Because the tumour grows slowly, recurrences may appear late, so long-term follow-up is advised (Carter, East and McHugh, 2018).
9. Follow-up
| Follow-up | Purpose |
|---|---|
| Nasal endoscopy every 3-6 months at first | Looks directly for recurrence |
| MRI | Often every 6-12 months, then less frequently |
| Eye and vision checks | If the eye socket was involved or treated |
| Long-term follow-up | Usually 10 years or more because of late recurrence |
10. Living with biphenotypic sinonasal sarcoma
- Use saline nasal rinses as advised to keep the nose clean
- Report new nasal blockage, bleeding or eye changes
- Attend all scans and endoscopies, even if you feel well
- Protect your eyes with lubricating drops if they become dry after radiotherapy
- Avoid smoking, which slows healing of the nasal lining
- Use a humidifier at night if your nose feels dry and crusted
- Tell any new doctor about your diagnosis, as follow-up may span many years
- Seek support from sarcoma and head and neck cancer charities
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is it a serious cancer? | It is a low-grade cancer; it can grow locally but rarely spreads |
| Is it caused by smoking? | No link has been found |
| Is it inherited? | No |
| Will I need chemotherapy? | Generally not |
| Can it come back? | Yes, which is why long-term follow-up is important |
| Will I lose my sense of smell? | It may be reduced, depending on the tumour’s position and the surgery |
| Can surgery be done through the nose? | In most cases, yes |
| Will I have a scar on my face? | Not usually with endoscopic surgery |
| How quickly does it grow? | Slowly, often over years |
| Can I fly after surgery? | Usually after a few weeks; ask your surgeon, especially after skull base repair |
12. Questions to ask your care team
- How far has the tumour spread into the eye socket or skull base?
- Can it be removed endoscopically?
- Were the margins clear?
- Do I need radiotherapy?
- Which fusion gene does my tumour have?
- How long will my follow-up last?
- What will happen to my sense of smell?
- Is this centre experienced in skull base surgery?
Resources
- Carter, C.S., East, E.G. and McHugh, J.B. (2018) ‘Biphenotypic sinonasal sarcoma: a review and update’, Archives of Pathology and Laboratory Medicine, 142(10), pp. 1196-1201.
- Jo, V.Y. et al. (2018) ‘Expression of PAX3 distinguishes biphenotypic sinonasal sarcoma from histologic mimics’, American Journal of Surgical Pathology, 42(10), pp. 1275-1285.
- Turri-Zanoni, M. et al. (2022) ‘Biphenotypic sinonasal sarcoma: European multicentre case-series and systematic literature review’, Acta Otorhinolaryngologica Italica, 42(6), pp. 545-553.
- Wang, X. et al. (2014) ‘Recurrent PAX3-MAML3 fusion in biphenotypic sinonasal sarcoma’, Nature Genetics, 46(7), pp. 666-668.
- National Cancer Institute (2026) Paranasal Sinus and Nasal Cavity Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/head-and-neck/hp/adult/paranasal-sinus-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.